Browsing: ResMed

SAN DIEGO – Resmed has a new collaboration with 23XI Racing and its NASCAR Cup Series driver Tyler Reddick to encourage more people to recognize the signs of sleep apnea and seek diagnosis and treatment. After being diagnosed with obstructive sleep apnea (OSA) and starting continuous positive airway pressure (CPAP) therapy in early 2026, Reddick went…

ResMed Inc. (NYSE:RMD) is one of the most undervalued large cap stocks to buy according to analysts. On June 1, ResMed finalized its acquisition of Noctrix Health, a medical device company known for developing non-pharmacologic wearable therapeutics. This strategic move expands ResMed’s clinical sleep health portfolio into the treatment of Restless Legs Syndrome/RLS, which is…

ResMed Inc (ASX:RMD) closed at AUD 31.48 at the close of trading on 6 August 2026, up 0.29% for the session. The broader S&P/ASX 200 Health Care (ASX: XHJ) Index advanced +0.81% to close at 28,235.50 points, while the S&P/ASX 200 (ASX: XJO) gained +0.47% to finish the day at 9,271.60 points

ResMed Inc (ASX:RMD) is a global medical device and digital health company that develops products for the diagnosis and treatment of sleep disorders and respiratory conditions. The company’s primary products include CPAP and other positive airway pressure devices used in the treatment of obstructive sleep apnea

ResMed (RMD) has drawn investor attention after recent share price gains over the past week and month, set against weaker returns over the past year and year to date

Resmed has agreed to sell its MatrixCare business in a $490m cash deal to PE firm Frazier Healthcare Partners, allowing it to dedicate its focus to its sleep health-related business interests

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource

Resmed (ASX:RMD) is a name that appears on the watchlists of many market participants following Australian health care stocks. As a medical device and digital health company, its story is closely bound up with the sleep and respiratory health technology sector and the broader mood across the health care space

The cleanest short thesis on ResMed (NYSE: RMD) is that weight-loss drugs could shrink the obstructive sleep apnea market over time and weaken demand for PAP devices. That framing is too narrow. ResMed is not just selling initial devices into a one-time diagnosis event. It operates a broader sleep-health ecosystem built around installed devices, recurring…